Dexcom (NASDAQ:DXCM) SVP Jeffrey Moy sold 59,193 shares of the firm’s stock in a transaction on Thursday, June 28th. The stock was sold at an average price of $92.48, for a total value of $5,474,168.64. Following the completion of the transaction, the senior vice president now directly owns 68,511 shares in the company, valued at $6,335,897.28. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Shares of Dexcom stock opened at $98.12 on Thursday. The stock has a market cap of $8.67 billion, a PE ratio of -169.17 and a beta of 0.01. The company has a quick ratio of 5.42, a current ratio of 5.83 and a debt-to-equity ratio of 0.79. Dexcom has a twelve month low of $42.62 and a twelve month high of $102.10.
Dexcom (NASDAQ:DXCM) last issued its quarterly earnings data on Wednesday, May 2nd. The medical device company reported ($0.32) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.32). The firm had revenue of $184.40 million during the quarter, compared to analyst estimates of $172.66 million. Dexcom had a negative return on equity of 9.32% and a negative net margin of 4.30%. The business’s quarterly revenue was up 29.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.49) earnings per share. analysts anticipate that Dexcom will post -0.51 earnings per share for the current fiscal year.
A number of equities analysts recently commented on DXCM shares. BTIG Research reaffirmed a “hold” rating on shares of Dexcom in a report on Thursday, May 3rd. Zacks Investment Research upgraded Dexcom from a “sell” rating to a “hold” rating in a research note on Friday, March 16th. Oppenheimer increased their price target on Dexcom from $80.00 to $85.00 and gave the stock an “outperform” rating in a research note on Thursday, May 3rd. Raymond James upgraded Dexcom from a “market perform” rating to an “outperform” rating in a research note on Monday. Finally, Piper Jaffray Companies set a $78.00 price target on Dexcom and gave the stock a “buy” rating in a research note on Friday, March 23rd. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $75.68.
Several institutional investors have recently modified their holdings of DXCM. Signaturefd LLC purchased a new position in shares of Dexcom during the first quarter valued at about $105,000. American International Group Inc. purchased a new position in shares of Dexcom during the fourth quarter valued at about $116,000. SG Americas Securities LLC purchased a new position in shares of Dexcom during the first quarter valued at about $175,000. Marco Investment Management LLC purchased a new position in shares of Dexcom during the fourth quarter valued at about $201,000. Finally, CIBC Asset Management Inc purchased a new position in shares of Dexcom during the first quarter valued at about $220,000.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.